A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
← catalyst calendarNCT07219407 · readout in 533 d
Sponsored by Rapport Therapeutics Inc. (industry) · RAPP — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-15 | actual | When the study began enrolling |
| Primary completion | 2028-02-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Focal Epilepsy
- Epilepsy
- Refractory Focal Epilepsy
- Seizure
- Focal Seizure
- Focal Onset Seizure
Intervention
- Drug: RAP-219
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured From the start of RAP-219 treatment through 8 weeks after last dose, up to Week 112
Permalink · RAPP's whole pipeline · Catalyst calendar · Every registered study · What changed